BBIO Stock Forecast & Price Target

BridgeBio Pharma's financial outlook is bolstered by an increase in revenue projections, with full-year 2026 revenue forecasted to rise to $766.3 million, reflecting positive momentum in the company's offerings. The successful launch of Attruby (acoramidis) has led to a steady increase in sales, with 5,259 unique patient prescriptions recorded and a positive response from key opinion leaders indicating that it may establish itself as a market leader in the ATTR-CM space. Additionally, promising clinical data from both BBP-418 and encaleret enhances investor confidence, as these candidates are on track for potential regulatory approval and could drive significant revenue generation in the coming years.

BridgeBio Pharma is projected to experience a significant net loss of $3.59 million for the full year of 2025, compounded by a recent quarterly net loss of $182.7 million, which exceeded consensus estimates. The company faces considerable financial pressure due to limited cash reserves and high debt levels, raising concerns about its capacity to sustain operations amid potential clinical or commercial setbacks. Additionally, the risk of competitive pressures in the ATTR-CM market, along with uncertainties regarding the efficacy of its pipeline candidates, further contribute to a challenging outlook for the company's financial health.